Drug companies' sexually explicit ads reaching too many youngsters

July 11, 2019

Virtually every day, millions of children and adolescents are being bombarded by sexually explicit direct-to-consumer advertising, despite pharmaceutical CEOs' claims to the contrary.

Leading business ethicist Denis Arnold from the University of North Carolina at Charlotte co-authored the study, "Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials," published in the just released Journal of Health Politics, Policy and Law. Jim Oakley, professor and chair of marketing at Lewis University, is the study co-author.

Arnold, the Surtman Distinguished Professor of Business Ethics in the Belk College of Business, and Oakley studied marketing campaigns for erectile dysfunction (ED) drugs during a six-year period. These products include sildenafil citrate, manufactured and marketed as Viagra in the United States by Pfizer; and tadalafil, manufactured and marketed as Cialis in the United States by Eli Lilly.

"PhRMA Guiding Principles," for which both companies have certified their compliance, state that 90 percent of the audience viewing sexually explicit advertisements must be 18 or older. These principles, developed by the Pharmaceutical Research and Manufacturers of America trade organization (PhRMA), were first introduced in 2005, and under these guidelines, a company must commit to internal processes to ensure compliance with the principles, complete an annual certification of compliance and submit a document to PhRMA signed by the CEO and chief compliance officer attesting to compliance.

"Pfizer and Eli Lily have never met the standard, and public disclosure of this misconduct in 2013 did not alter their behavior," stated Arnold, past president of the Society for Business Ethics. "The most reasonable explanations for this misconduct are that a public commitment to the standard helps block additional regulation, while at the same time there are no penalties for routinely violating the standard.

"Firms continued to aggressively advertise ED drugs when they knew children and adolescents would be exposed to these sexually explicit ads billions of times," Arnold added.

In 2013, Arnold and Oakley published a research article also in the Journal of Health Politics, Policy and Law that found firms never met the industry standard during a different four-year period they analyzed. This study was widely publicized and acknowledged by the manufacturers of ED drugs and PhRMA. In this new study, Arnold and Oakley sought to answer this question, "Would public disclosure of non-compliance with industry standards improve firm behavior?" The answer, as determined by their recent study, is "no." Eric Patashnik, editor-in-chief of the Journal of Health Politics, Policy and Law and the Julis-Rabinowitz Professor of Public Policy and Professor of Political Science at Brown University, stated,

"Broadly, they [Arnold and Oakley] found that public disclosure did not cause firms to alter their behavior, suggesting that the pharmaceutical industry is simply not willing to police itself."

Other findings from "Self-Regulation in the Pharmaceutical Industry: The Exposure of Children and Adolescents to Erectile Dysfunction Commercials" include:

University of North Carolina at Charlotte

Related Erectile Dysfunction Articles from Brightsurf:

European survey shows alarmingly low awareness of erectile dysfunction
Awareness of erectile dysfunction (ED) is alarmingly low in men and women aged 20 to 70, a new survey commissioned by the European Association of Urology (EAU) has revealed.

Erectile dysfunction drugs can help cells destroy misfolded proteins
PDE5 inhibitors -- which include the erectile dysfunction drugs sildenafil and tadalafil -- can activate the cell's protein quality-control systems and improve its ability to dispose of misfolded proteins.

Men with erectile dysfunction may face higher risk of death
Men with erectile dysfunction have a higher risk of death, regardless of their testosterone levels, suggests a study accepted for presentation at ENDO 2020, the Endocrine Society's annual meeting, and publication in a special supplemental section of the Journal of the Endocrine Society.

Factors associated with discontinuation of erectile dysfunction treatment
The factors associated with men ending treatment for erectile dysfunction have been reviewed in a study published in IJIR: Your Sexual Medicine Journal.

Concussions linked to erectile dysfunction in former NFL players
Former NFL players reporting concussion symptoms following head injury more likely to report erectile dysfunction and low testosterone levels.

Erectile dysfunction associated with lower work productivity in men
Erectile dysfunction (ED) was linked with loss of work productivity and with lower health-related quality of life in an International Journal of Clinical Practice study of more than 52,000 men from eight countries.

The global prevalence of erectile dysfunction
A review of published studies found that estimates for the global prevalence of erectile dysfunction vary widely, ranging from 3% to 76.5%.

Improved procedure for cancer-related erectile dysfunction
Melbourne surgeons have modified a minimally invasive technique to help men regain erectile function lost after prostate cancer surgery.

New discovery provides key to side effects caused by erectile dysfunction drugs
Study reveals several features of PDE6 that were previously unseen.

Convincing evidence that type 2 diabetes is a cause of erectile dysfunction
Evidence that type 2 diabetes is a cause of erectile dysfunction has been found in a large-scale genomic analysis.

Read More: Erectile Dysfunction News and Erectile Dysfunction Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.